ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM
By Elana Gotkine HealthDay Reporter
FRIDAY, April 4, 2025 -- For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment with dulaglutide, according to a study published online April 4 in the Annals of Internal Medicine to coincide with the Internal Medicine Meeting, the annual meeting of the American College of Physicians, held from April 3 to 5 in New Orleans.
Liana K. Billings, M.D., from the Pritzker School of Medicine at the University of Chicago, and colleagues conducted a multicenter, randomized, phase 4 trial to compare the efficacy and safety of escalation of dulaglutide dose versus switching to tirzepatide in inadequately controlled type 2 diabetes. A total of 828 adults with HbA1c 7.0 percent or greater to 9.5 percent or less, stable body weight, and body mass index of 25 kg/m2 or greater receiving a stable dose of dulaglutide (0.75 or 1.5 mg) for at least six months were randomly assigned to tirzepatide or escalation of dulaglutide (139 and 143, respectively).
The researchers found that at week 40, the change from baseline in HbA1c was −1.44 and −0.67 percent with tirzepatide and dulaglutide escalation to 4.5 mg or maximum tolerated dose, respectively. The change from baseline in weight at week 40 was −10.5 and −3.6 kg with tirzepatide and dulaglutide, respectively. Overall, 7.2 and 7.0 percent of tirzepatide- and dulaglutide-treated patients, respectively, had serious adverse events. Nausea and diarrhea were the most common treatment-emergent adverse events reported.
"Once-weekly treatment with tirzepatide resulted in significantly greater HbA1c and weight reductions compared with continuing and escalating dulaglutide treatment," the authors write.
The study was funded by Eli Lilly, the manufacturer of tirzepatide.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Stratifying BMI by Waist Circumference Improves Mortality Risk Prediction in Postmenopausal Women
THURSDAY, July 10, 2025 -- Stratifying body mass index (BMI) categories by waist circumference (WC) thresholds improves mortality risk prediction in postmenopausal women...
New Framework Reclassifies Nearly 20 Percent of People as Having Obesity
WEDNESDAY, July 9, 2025 -- The European Association for the Study of Obesity (EASO) framework may offer a more sensitive measure of obesity than traditional body mass index (BMI)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.